Anger management: Statins decrease aggression in men, increase it in women

Statins decreased aggression in adult men and increased aggression in postmenopausal women, according to a randomized, double-blind, placebo-controlled trial published online July 1 in PLOS One.

Lead researcher Beatrice A. Golomb, MD, PhD, of the University of California, San Diego, and colleagues randomized 1,016 adults to receive a statin (simvastatin or pravastatin) or placebo for six months. The patients included 692 men who were at least 20 years old and 324 surgically or chronologically postmenopausal women. They were excluded if they had cardiovascular disease, cancer (except for nonmelanoma skin cancer), HIV, diabetes, fasting blood glucose >142 mg/dL or low density lipoprotein (LDL) cholesterol <115 mg/dL or >190 mg/dL.

The groups were well balanced; the mean age was 57 years, 81 percent of patients were white and 68 percent were male.

To measure aggression, Golomb and colleagues used the OASMa (Overt-Aggression-Scale-Modified) scale, which measures behavioral aggression such as verbal assaults, assaults against objects, assault against others and assaults against self.

For women, statins increased aggression, especially for women who were 45 or older and those who were less aggressive at baseline.

"Those with evidence of aggression at baseline have other forces acting on aggression, and may be subject to more variance in aggression arising from sources distinct from statins," wrote Golomb and colleagues.

For men, statins decreased aggression, particularly for those taking pravastatin as well as younger men and men who were less aggressive. However, three men who took statins had a large increase in aggression, according to the researchers.

There were two deaths in the study. One participant in the pravastatin group committed suicide, while one participant in the placebo group was found dead in his room. Although no autopsy was performed, the person was determined to have heart failure. In addition, one woman in the pravastatin group discontinued the study at her husband’s urging because she had an adverse behavioral change. The woman told researchers that the changes led to her being fired from her job.

All groups had a lowering of LDL cholesterol, and the mean decrease was significantly greater with simvastatin compared with pravastatin.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.